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Abstract objective To evaluate HIV drug resistance (HIVDR) and determinants of virological failure in a
large cohort of patients receiving first-line tenofovir-based antiretroviral therapy (ART) regimens.
methods A nationwide retrospective cohort from 42 health facilities was assessed for virological
failure and development of HIVDR mutations. Data were collected at ART initiation and at
12 months of ART on patients with available HIV-1 viral load (VL) and ART adherence
measurements. HIV resistance genotyping was performed on patients with VL ≥1000 copies/ml.
Multiple logistic regression was used to determine factors associated with treatment failure.
results Of 828 patients, 66% were women, and the median age was 37 years. Of the 597 patients
from whom blood samples were collected, 86.9% were virologically suppressed, while 11.9% were
not. Virological failure was strongly associated with age <25 years (adjusted odds ratio [aOR]: 6.4;
95% confidence interval [CI]: 3.2–12.9), low adherence (aOR: 2.87; 95% CI: 1.5–5.0) and baseline
CD4 counts <200 cells/ll (aOR 3.4; 95% CI: 1.9–6.2). Overall, 9.1% of all patients on ART had
drug resistance mutations after 1 year of ART; 27% of the patients who failed treatment had no
evidence of HIVDR mutations. HIVDR mutations were not observed in patients on the recommended
second-line ART regimen in Rwanda.
conclusions The last step of the UNAIDS 90-90-90 target appears within grasp, with some viral
failures still due to non-adherence. Nonetheless, youth and late initiators are at higher risk of
virological failure. Youth-focused programmes could help prevent further drug HIVDR development.
keywords HIV, drug resistance, tenofovir, Rwanda, viral failure
Introduction
The increasingly widespread use of antiretroviral therapy
(ART) has substantially improved the prognosis of people
living with HIV. Mortality among persons on ART has
fallen and may now be no higher than for other chronic
diseases, even in resource-limited settings (RLS) [1, 2].
Rwanda achieved universal ART coverage in 2012, when
more than 90% of people in need of ART (according to
national guidelines) received drug therapy [3]. The suc-
cess of the national HIV programme translates to a vari-
ety of favourable indicators including an increase in life
expectancy of HIV-infected Rwandans that is near the
life expectancy of uninfected individuals [2]. Despite
these successes, HIV drug resistance poses a growing
threat to the ongoing success and durability of ART
regimens during the continued ART scale-up in many
countries [4].
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According to a systematic review in 2011, the overall
transmitted HIV drug resistance in RLS was 6.6% and
negatively impacted outcomes of first-line ART [5, 6].
Genotyping tests performed on eight patients in a Rwan-
dan study evaluating drug resistance mutations (DRMs)
among patients on first-line ART found two cases with
thymidine analogue mutations (TAMs) [7]. The muta-
tions included D67N, K70R and K219Q in one case and
D67N and K70R in the other [7]. Likewise, Mutwa et al.
found TAMs in 31% of 57 children and adolescents who
had virological failure on first-line ART.[8] However, all
DRM studies conducted in Rwanda took place when the
guidelines recommended thymidine analogues (i.e. zido-
vudine and stavudine) for first-line ART [9]. Since 2009,
the Rwanda ART guidelines have recommended tenofovir
(TDF)-based regimens for ART-na€ıve patients [10]; TDF
selects the K65R mutation rather than TAMs.[11, 12]
A number of studies that evaluated drug resistance
after 12 months of ART in RLS have been conducted,
but most of these had small numbers of patients. Studies
on DRMs within Rwanda have also been based on small
numbers of patients and were focused on mutations asso-
ciated with thymidine analogues rather than TDF-based
regimens. This study aimed to address both gaps by eval-
uating DRMs after 12 months on ART among a large
national sample of patients, the majority of whom started
TDF-based regimens as their first-line therapy.
Methods
Study setting and study design
At the end of 2010, 83 041 Rwandans were on ART in
295 health facilities. ART coverage was at 75.5% [13,
14]. Eligibility criteria to start ART in 2010 were WHO
clinical stage IV, or a CD4 cell count <350 cells/ll.
Exceptions were patients with TB/HIV co-infection and
pregnant women, whose ART treatment was initiated for
life when CD4 cell counts were <500 cells/ll. First-line
ART consisted of TDF and lamivudine (3TC) in combi-
nation with one NNRTI (either nevirapine or efavirenz).
Patients received individual counselling at each clinic
visit, both before and during ART. Biological follow-up
of outcomes of ART consisted of CD4 monitoring every
6 months and HIV-1 viral load monitoring once per year.
We conducted a nationwide retrospective cohort study
based on the WHO generic protocol for evaluating the
emergence of HIV-1 drug resistance [15]. A blood speci-
men and related demographic and clinical information
was collected from ART patients starting their first year
of treatment. Using an electronic monitoring and evalua-
tion database (TRACnet) [16], we selected 42 health
facilities among the 269 that were ART sites by the end of
2009. Eligibility criteria for inclusion of health facilities
were that the facilities had functioned as an ART site for
at least 1 year, so that programme functioning was well
established and enrolment of at least one patient per month
between November 2010 and January 2011. Health facili-
ties with larger numbers of patients on ART were also
enrolling larger numbers of patients initiating ART.
Inclusion criteria applied to patients in these 42 health
facilities were as follows: age 15 years and older) and on
first-line ART for 12 months (1 month). Patients who
were known to have received single-dose nevirapine as pre-
vention of mother-to-child HIV transmission prior to start-
ing ART and patients who received other ART prophylaxis
for other reasons were also included. We excluded patients
who were transferred from other health facilities to avoid
missing information preceding enrolment, children (below
15 years of age) and patients who had stopped ART and
were restarting in the study period.
Data Collection
Initially, 837 patients who started ART between November
2010 and January 2011 and completed 12 months of
treatment by December 2011 met the inclusion criteria.
However, due to missing medical files, we removed nine
patients and were left with 828 within our retrospective
cohort. This cohort was composed of patients still alive and
active in the programme, those lost to follow-up and those
who had died and/or transferred out. Of these, 711 patients
were still active in the programme and were invited for
blood collection. Through healthcare providers, we invited
them for a fixed data collection day; 597 patients (84% of
invited) presented themselves on data collection day and
consented to give a blood sample for HIV-1 viral load and
resistance genotyping. We conducted verbal interviews
using personal digital assistant and chart reviews by trained
data collectors to record information on all 828 patients.
Blood samples for the 597 consenting patients were
obtained using standard methods for blood sample pro-
cessing. HIV-1 viral load testing was performed at the
National Reference Laboratory in Kigali, Rwanda, using
the Roche system CAP/CTM (COBAS AmpliPrep and
COBAS TaqMan 96) with Kit HI2CAP. One millilitre of
plasma from each blood draw was stored at 80 °C for
use in future analysis. Seventy-one samples having a viral
load of ≥1000 copies/ml were analysed for the presence
of ART resistance mutations using the TRUGENE HIV-1
Genotyping Assay on the OpenGene DNA System (Sie-
mens HealthCare, USA) at the College of American
Pathologist-accredited HIV Diagnostics and Reference
Laboratory at the Walter Reed Army Institute of
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Research in Maryland, USA. Seventy samples were suc-
cessfully sequenced; one sample failed to amplify three
times and another sample after a failure yielded a
sequence having high background and of poor quality.
ART resistance mutations and subsequent susceptibility
profiles were generated with Siemens FDA-approved Gen-
eObjects 4.1 software and Guidelines 17.0. HIV-1 sub-
type was determined using phylogenetic tree analysis of
the sequences against selected reference sequences using
MegAlign (DNASTAR, Inc., Madison WI, USA), Stan-
ford HIV Drug Resistance Database (http://hivdb.stan-
ford.edu), HIV-1 BLAST analysis of each region
(www.hiv.lanl.gov/content/sequence/BASIC_BLAST/ba-
sic_blast.html) and the HIV sequence database subtyping
tool (www.hiv.lanl.gov). Protease and reverse transcrip-
tase sequences for each specimen were submitted to Gen-
Bank (Accession numbers KU922763 – KU922832 and
KU922833 – KU922902, respectively).
Variable Definition
The primary outcome of interest in this study was HIV
drug resistance (HIVDR). HIVDR outcomes were defined
according to WHO protocol [1] as (i) prevention of
HIVDR when an HIV RNA viral load was <1000 copies/
ml; (ii) potential HIVDR (virological failure) when HIV
RNA was ≥1000 copies/ml with no observation of HIVDR
mutations in the genotype test; and (iii) HIVDR when HIV
RNA was ≥1000 copies/ml with HIVDR mutations
observed in genotypic testing. HIV RNA viral load sup-
pression was defined as viral load <400 copies/ml.
For this research, ‘retention’ was a multicategory vari-
able that established the proportion of patients known to
be alive and receiving ART, that transferred out, that
were known and documented to have died 12 months
after ART initiation and that were lost to follow-up
according to the national definition. Patients were sched-
uled to have monthly clinic visits and drug pickups. They
were deemed to be lost to follow-up if they failed to pre-
sent themselves for three consecutive visits/pickups.
We collected information on sociodemographic charac-
teristics, previous ART exposure, clinical baseline infor-
mation, initial ART prescription and any prescription
following a switch within 12 months, and immunological
evolution. Adherence was evaluated by visual analogue
scale during the 30 days prior to data collection and by
appointment keeping records from pharmacies.
Statistical analysis
We used descriptive statistics to describe the sample with
respect to sociodemographic and clinical characteristics
and to describe the various types of mutations present in
the sample. Using univariate and multivariate logistic
regression, a number of variables were examined as inde-
pendent predictors of virological failure and drug resis-
tance. For each potential predictor, including age, sex,
marital status, type of health facility, ever attended
school, active tuberculosis when starting ART and self-
reported adherence during the last 30 days, we first cal-
culated the odds ratio with 95% confidence intervals
using univariate logistic regression. Model selection
within the multivariate analyses was completed by identi-
fying the model that minimised the Akaike’s information
criterion (AIC). Data analysis was performed using SPSS
for Windows, Version 16.0. Chicago, SPSS Inc.
Ethics
Written informed consent for conducting an interview
and taking a blood sample was obtained from all patients
prior to any procedure. The protocol for this study was
approved by the National Research Committee on HIV/
AIDS and by the Rwanda National Ethics Committee.
Results
Patients’ characteristics and retention after 12 months of
ART
A total of 828 adult patients were included, of whom 552
(66%) were female. Table 1 presents the baseline charac-
teristics of the cohort. The median age was 37 years (IQR:
30–45), and youth (≤25 years) comprised 10% of partici-
pants. Overall, 62% had ever attended school and among
them 75% had only ever attended primary school; 60% of
the study population were in a partner relationship with
39% married and 21% cohabitating.
Of 828 adult patients who initiated first-line ART and
remained on therapy for 12 months, 711 (85.9%) were
still taking their first-line ART regimen from the same
site of ART initiation (i.e. that they did not change their
original prescribed ARVs and were not transferred out),
66 patients (8%) were transferred out to other ART
health facilities, 27 patients (3.2%) had died, and 23
patients (2.7%) were lost to follow-up at 12 months.
Only one patient stopped ART and one person switched
ART regimens.
Clinical, immunology and virological outcomes
The median CD4 count was 273 cells/ll (IQR: 175–331
cells/ll) at ART initiation, 392 cells/ll (IQR: 256–533
cells/ll) at 6 months and 420 cells/ll (IQR: 269–587
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cells/ll) at 12 months. At baseline, 29% of patients had
advanced immunosuppression (CD4 < 200 cells/ll); half
of patients (51%) were in WHO clinical stage I, 28% in
stage II, 17% in stage III and 4% in stage IV. At ART
initiation, 6% of all participants were also taking antitu-
berculosis drugs and 3% developed tuberculosis between
ART initiation and 12-month follow-up. The majority of
patients (96%) initiated TDF-based regimens. Median
adherence using visual analogue scale was 97% over the
past 30 days.
Virological and drug resistance outcomes
Among 597 samples collected, 587 underwent analysis,
and among those, 507 (86.4%) had suppressed their VL
(VL < 400 copies/ml), 71 (12.1%) had virological failure
(VL ≥1000 copies/ml), and 9 (1.5%) were between 400
and 999 copies.
Table 2 presents the results of the logistic regression
analyses for virological failure as an outcome. Virological
failure was strongly associated with age below 25 years
(adjusted odds ratio [aOR]: 6.4; 95% confidence interval
[CI]: 3.2–12.9; P < 0.001), low adherence (aOR: 2.87;
95% CI: 1.5–5.0; P < 0.001) and CD4 count <200 cells/ll
(aOR 3.4; 95% CI: 1.9–6.2; P < 0.001) at ART initiation.
There was no significant association between virological
failure, sex, education level, type of health facility, previ-
ous ART exposure or active tuberculosis at ART initiation.
Genotype sequencing was performed on the 71 samples
with HIV-1 RNA VL ≥1,000 c/ml. Seventy samples were
successfully sequenced; one sample did not amplify (three
times) and no sequence was obtained. The predominant
HIV subtype was A1 at 77.1% followed by C at 12.9%
and D at 5.7% (Table 1). HIVDR mutations were
observed in 9.1% of the patients (54/590), while DR
mutations were observed in 2.7% (16/590). Table 3 lists
the mutations identified along with their frequencies. The
predominant nucleoside reverse transcriptase inhibitor
(NRTI) mutations were M184V (55.7%) and K65R
(41.4%), but thymidine analogue mutations were few,
and no complete pathway was found. For non-nucleoside
reverse transcriptase inhibitors (NNRTI), the most com-
mon mutations were Y181C, K103N and G190A with
frequencies of 41%, 20% and 17%, respectively. Finally,
minor resistance mutations at amino acid positions L10
and K20 were observed for protease inhibitors (PI) except
for the predominance of the polymorphism M36I.
Interpretation of these mutations showed that 16
(22.9%) patients who had virological failure did not har-
bour any resistance mutations and 54 (77.1%) had at
least one resistance mutation. The frequencies of resis-
tance to at least one ARV medication were 62.1% for
NRTIs, 74.7% for NNRTIs and 12.9% for PIs. With
respect to resistance to an entire drug class, 27% of
patients were resistant to NNRTIs, but no patients were
completely resistant to NRTIs or PIs. Among 70 success-
ful sequenced samples, 42.9% had virus resistant to 5
NRTIs used in Rwanda (ABC, ddI, 3TC, d4T, TDF)
except AZT. Moreover, 38.5% of patients resistant to
Table 1 Baseline patient characteristics
Variable Count (percentage) or Median (IQR)
Age (in years) (n = 828) 37 (30–45)
<25 years 83 (10.0)
≥25 years 745 (90.0)
Sex (n = 828)
Female 547 (66.1)
Male 281 (33.9)
Marital Status (n = 754)
Single 105 (13.9)





Ever to school (n = 650)
No 133 (20.5)
Yes 517 (79.5)
WHO stage baseline (n = 819)
WHO I 422 (51.5)
WHO II 228 (27.8)
WHO III 137 (16.7)
WHO IV 32 (3.9)
CD4 at baseline (n = 799)
≤200 CD4 228 (28.5)
>200 CD4 571 (71.5)
ART exposure before HAART (n = 719)
Yes 63 (8.8)
No 656 (91.2)
Reason of ART exposure (n = 58)
PMTCT prophylaxis 51 (87.9)
PMTCT and PEP 3 (5.2)
PEP only 4 (7.0)
TB at baseline (n = 783)
Yes 45 (5.7)
No 738 (94.3)
Level of health facility (=828)
Health Centre 341 (41.2)
District Hospital 470 (56.8)







1 B/A 1 (1.4)
Total 70 (100)
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these 5 NRTIs were also resistant to all NNRTIs used in
Rwanda (EFV, NVP and ETR). Patients who were on an
NVP-based regimen were at six times greater risk of
developing at least one drug resistance mutation than
patients on an efavirenz-based regimen (OR 6.6; P-value
0.01). Among patients with virological failure, the major-
ity (54; 77.1%) shifted from first-line ART to second-line
ART due to the resistance mutations that developed.
There was no significant association between developing
drug resistance mutation and age <25 years.
Table 4 presents the frequency of resistance to specific
ARVs. Among 70 samples with successful sequencing,
58% had virus resistant to 3TC, 44% to TDF and 43%
to ABC, DDI and D4T. For NNRTIs, 76% had virus
resistant to NVP and sensitivity to EFV and ETR at 24%
and 44%, respectively. All available protease inhibitors
and zidovudine were 100% sensitive.
Discussion
Our study provides a novel assessment of the drug resis-
tance mutations among patients who started on TDF-
based regimens in Rwanda. This study was required as
previous studies on HIVDR in Rwanda were conducted
on patients who received thymidine analogue-based first-
line treatments, which are no longer the primary first-line
therapies in Rwanda [17]. We found that after
12 months of ART, 88.1% of patients suppressed their
VL and virological failure was 12%. Among those with
virological failures, 22.9% (16/70) were failing ART
without a drug resistance mutation (potential drug resis-
tance). The remaining 77.1% (54/70) had drug resistance
mutations and were shifted to second-line ART regimens.
The predominant mutations identified were M184V and
K65R for NRTI, Y181C for NNRTIs, K103N and
G190A for NNRTIs and minor mutations for PIs. Viro-
logical failures were associated with young age, subopti-
mal adherence and low CD4 at ART initiation.
The success of HIV drug treatment met the WHO rec-
ommendation of >85% of patients on ART suppressing
HIV-1 VL after 12 months of treatment. At 88.1% viral
suppression after 12 months on treatment, Rwanda seems
within reach of the third step of the 90-90-90 target
recently set by UNAIDS [18]. Viral suppression results
Table 2 Predictors of virological failure
Patients’ characteristics VL > 1000 copies/ml n (%) VL < 1000 copies/ml n (%)
Univariate analysis Multivariate analysis
OR (95% CI) OR (95% CI)
Age
<25 years 22 (33.8) 43 (66.2) 5.0 (2.7–9.1) 6.4 (3.2–12.9)
≥25 years 48 (9.2) 472 (90.8)
Sex
Male 19 (10.0) 170 (90.0) 0.7 (0.4–1.3)
Female 51 (12.9) 345 (87.1)
Marital status
Not union 35 (15.6) 189 (84.4) 1.7 (1.0–2.8) 1.3 (0.7–2.3)
In union 35 (9.8) 322 (90.2)
Self-report adherence
Adherence by VAS < 95% 23 (23.7) 74 (76.3) 2.9 (1.6–5.0) 2.7 (1.5–5.0)
Adherence by VAS ≥ 95% 47 (9.6) 515 (90.4)
Ever to school
No 13 (11.5) 100 (88.5) 0.9 (0.5–1.8)
Yes 57 (12.3) 406 (87.7)
CD4 at ART initiation
≤200 CD4 29 (19.6) 119 (80.4) 2.4 (1.4–4.0) 3.4 (1.9–6.2)
>200 CD4 39 (9.2) 383 (90.8)
ART exposure before
Yes 8 (16) 42 (84) 1.4 (0.6–3.2)
No 61 (11.5) 468 (88.5)
TB at ART initiation
Yes 1 (4.0) 24 (96.0) 0.3 (0.04–2.2)
No 68 (12.2) 491 (87.8)
Type of heath facility
Public 59 (12.8) 402 (87.2)
Mission 11 (8.8) 114 (91.2) 1.5 (0.8–3.0)
OR: odds ratio; CI: confidence interval. Values in bold are statistically significant at the 0.05 significance level.
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were comparable to those found by Rusine et al. in a
smaller prospective cohort of 213 patients on ART in
Kigali where 86% achieved HIV viral suppression [7,
19]. Another retrospective study conducted in Rwanda
by Frank et al. found 85% of patients virally suppressed
after 12 months on ART [20]. Likewise, other countries
in RLS such as Malawi, Mali, Burkina Faso and South
Africa reported that HIV-1 suppression with ART was
between 85% and 88% [17, 21, 22].
In our study, treatment failure was associated with
age being <25 years. A similar result was reported in a
Kenyan cross-sectional study of 238 patients on ART
where patients aged 15–35 years were more likely to
experience virological failure [23]. Qualitative studies
have suggested that low adherence to treatment particu-
larly in adolescents may explain the higher risk of ART
failure [24]; however, our model suggests that even
when adjusting for adherence, young patients remain at
higher risk of virological failure. This is of particular
concern given that ART is a lifelong engagement and
that they will have many years of treatment ahead of
them. Requiring second-line treatment early on could
lead to important complications in the future. There are
two possible explanations for youth being associated
with viral failure independently of adherence. First, it
may be indicative of transmitted HIV drug resistance.
Second, it may be due to measurement bias given that
adherence is measured in the past 30 days. Thus, poor
adherence in the first few months of ART could go
unnoticed and certainly could lead to drug resistance.
The association between virological failure and late initi-
ation has been reported by others, such as Matthew
et al. who followed a cohort of 820 patients in South
Africa and found that the risk of failure was nearly
double among those with CD4 counts ≤200 cells [25].
The findings emphasise the reason why early treatment
initiation is good, not only in preventing morbidity,
mortality and decreasing transmission but also in pre-
venting HIV drug resistance. Low adherence has long
been known to lead to HIV drug resistance, so observ-
ing this in our data was expected. The Rwanda national
HIV programme provides basic adherence counselling
and has community outreach to minimise loss to follow-
up. These findings highlight a need for enhanced adher-
ence interventions among the youth in HIV care.
Among patients with virological failure, 77.1% har-
boured at least one drug resistance mutation and as such
were indicated to shift to second-line ART. This propor-
tion is similar to a smaller Nigerian study that found
77.7% (14/18) of its participants had major drug resis-
tance mutation to either NRTIs or NNRTIs [26], and in
the study conducted by Ziada El-Khatib, 78% of failing
patients presented at least one major resistance mutation
[17]. However, 22.9% of patients with VL failure pre-
sented only wild-type virus (no drug resistance mutation
found), indicating the failure is likely due to poor use of
ART rather than failure of the ART itself. These patients
were kept on first-line ART, and adherence was
Table 3 Resistance mutations by drug class
NRTIs (N = 70) NNRTIs (N = 70) PIS (N = 70)
Mutation Frequency Per cent Mutation Frequency Per cent Mutation Frequency Per cent
M184V 39 55.7 Y181C 29 41.4 L10I 24 34.3
K65R 29 41.4 K103N 14 20.0 L10V 9 12.9
A62V 8 11.4 G190A 12 17.1 L33F 2 2.9
K70E 6 8.6 A98G 8 11.4 V11I 1 1.4
Y115F 5 7.1 V90I 8 11.4 L10I/M 1 1.4
K219E 5 7.1 V108I 7 10.0 L33V 1 1.4
K219R 1 1.4 K101E 6 8.6 A71T 1 1.4
K70E/R 1 1.4 Y181I 3 4.3
V75I 1 1.4 G190S 2 2.9
V75M 1 1.4 K101N 1 1.4
D67N 1 1.4 F227L 1 1.4
K70R 1 1.4 Y188L 1 1.4
M184I 1 1.4 Y181C*/V 1 1.4
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reinforced by the study team. Thus, drug resistance moni-
toring prevented the premature switching from first line
to second line in patients failing ART after 12 months.
The predominant drug resistance mutations for NRTIs
were K65R and M184V and for NNRTIs were Y181C
and K103N. These mutation sites were corroborated by
other studies where Hassan et al. found that M184V was
predominant (43.6%) in Kenya [23], and the predomi-
nance of M184V and K103N was found by Rusine et al.
and Ziada El-Khatib [7, 17]. However, the predominance
of K65R in our study differs from other studies men-
tioned due to use of TDF instead of thymidine analogue-
based regimen. Indeed, a large portion of patients had
virus resistant to all NRTIs used in Rwanda except the
thymidine analogue zidovudine, for which there was neg-
ligible resistance. Given that lamivudine has residual anti-
HIV activity despite the presence of resistance [27], the
use of zidovudine in combination with lamivudine and
boosted lopinavir or atazanavir as the choice second-line
regimen is viable despite the large number of individuals
with a large number of HIV drug resistances. As the
K65R is a dead-end mutation (in contrast to the TAM
pathways), use of a TDF-based first-line regimen allows
for a viable second-line regimen using zidovudine with a
boosted PI (particularly as K65R increases zidovudine
susceptibility). This differs from failure on a thymidine
analogue (zidovudine or stavudine) first-line regimen
where full TAM pathway resistance mutations eliminate
the viability of standard second-line regimens, allowing
only for monotherapy with boosted PIs.
Although this study succeeded in updating the Rwandan
HIVDR profile using a cohort of patients initiating TDF-
based regimens, doing so with a much larger sample than
comparable studies, it has several limitations. As we col-
lected information from health facilities’ documents, the
data were not always available. Attrition bias was possible
due to the patients who were not present to provide blood
on data collection day; however, comparisons of patient
characteristics between those whomissed and were present
on blood collection day did not reveal any meaningful dif-
ferences. Another probable bias is usage of visual analogue
scale in 30 previous days for the assessment of adherence,
which would include recall and social desirability biases. In
this study, we did not trace patients to confirmwhether they
were still alive or not and the rate of transfers was high. This
might reduce the rate of patients still alive on ART.
In conclusion, the monitoring of HIV drug resistance
in Rwanda showed that HIV viral suppression (88.8%)
which contributes to prevention of HIV drug resistance
was greater than the WHO target at >85%. Prevalence
of HIV drug resistance was 9%, and potential drug resis-
tance was 2.7%. Among patients who are failing first-line
ART in Rwanda 22.2% had wild-type virus (no drug-
associated mutations), which means that they are likely
failing due to poor ART adherence. The national HIV
programme should focus on improving HIV services to
adolescents and youth and to reinforce adherence among
patients on ART in order to reduce the proportion of
patients developing HIVDR.
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Table 4 Resistance and sensitivity of individual antiretroviral
drugs
Class ARV % Resistant Probable resistance Sensitive
NRTIs 3TC 58.6 4.3 37.1
TDF 44.3 4.3 51.4
ABC 42.9 0.0 57.1
DDI 42.9 0.0 57.1
D4T 42.9 0.0 57.1
AZT 0.0 0.0 100.0
NNRTIs NVP 75.7 0.0 24.3
EFV 31.4 44.3 24.3
RLP 28.6 1.4 70.0
ETR 1.4 54.3 44.3
PIs SQV 8.6 4.3 87.1
TPV 1.4 0.0 98.6
ATV 0.0 0.0 100.0
RIT 0.0 0.0 100.0
LPV 0.0 0.0 100.0
FPV 0.0 0.0 100.0
IDV 0.0 0.0 100.0
NFV 0.0 0.0 100.0
DRV 0.0 0.0 100.0
ABC, Abacavir; AZT, Zidovudine; DDI, Didanosine; 3TC, Lami-
vudine; D4T, Stavudine; TDF, Tenofovir; NVP, Nevirapine;
EFV, Efavirenz; ETR, Etravirine; ATV, Atazanavir; RIT, Riton-
avir; DRV, Darunavir; LPV, Lopinavir; SQV, Saquinavir; NFV,
Nelfinavir; TPV, Tipranavir, IDV, Indinavir; FPV, Fosampre-
navir; RLP, Rilpivirine.
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